-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Anika Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Anika Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $193K.
- Anika Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$6.33M, a 20.1% decline from 2022.
- Anika Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$5.27M, a 198% decline from 2021.
- Anika Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$1.77M, a 50.2% increase from 2020.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)